A new bio-technology plant for the pharmaceutical company Richter Gedeon was opened in Debrecen on Thursday. The project is worth HUF 25bn. At the opening ceremony, the Prime Minister said that this and similar projects indicate that Hungary has begun to recover from the failures of the past and to move forward.
The Prime Minister said that developments in Hungary are signs that the country has started to ‘recover from the failures of the past and has started to find its feet, albeit slowly and with some difficulty. Hungary is gradually finding its way back to the right path, and is returning to where it naturally belongs: among the winners.’
The Prime Minister said that every investment sends the message that Hungary is moving forward. Hungarian businesspeople have understood that a new era has begun worldwide, that ‘the world of speculation is in decline’ and now the time has come for those who want to make a living from work. Once more the guide is common sense, which has always taught us that expertise combined with hard work creates prosperity.
Mr. Orbán said that he is sure that underlying the investments of Hungarian companies is the fact that Hungary is becoming one of the most competitive countries in the Central European region, which is itself advancing once more. ‘If we do not allow ourselves to be dissuaded and diverted from our path, if we can utilize the opportunity presented by the fact that the role of this region is becoming more important in the continent and the whole world, than the next five to ten years will see the strengthening and advancement of the Central European region,’ the Prime Minister said.
The Richter project received nearly HUF 1.4bn of state funding. The investment will increase the local competitiveness of the North Alföld region of Hungary. The plant, which has a minimal environmental footprint, will initially start working on samples needed for clinical tests, which have extremely high intellectual and technological added value, and which will also appear on the market. Production will start in 2014. The resulting drugs will be protein products of mammalian cells grown in bioreactors, such as antibodies for treatment of cancer and chronic inflammatory diseases
(kormany.hu)
